Clinical trial
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in…
NCT00291473 · Ludwig Institute for Cancer Research, Other · Completed
Key facts
| NCT number | NCT00291473 |
|---|---|
| Title | Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers |
| Official title | Safety and Immunogenicity of Cholesterol-Bearing Hydrophobized Pullulan HER2 Protein 146 (CHP-HER2) and NY-ESO-1 Protein (CHP-NY-ESO-1) in Combination With OK-432 in HER2- and/or NY-ESO-1-Expressing Cancers |
| Lead sponsor | Ludwig Institute for Cancer Research, Other |
| Collaborators | Mie University |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Lung Cancer, Stomach Cancer, Breast Cancer, Ovarian Cancer |
| Intervention type | Drug |
| Interventions | CHP-HER2, CHP-NY-ESO-1 |
| Enrollment | 9 |
| Start date | Jul 1, 2005 |
| Primary completion | Aug 1, 2008 |
| Completion | Aug 1, 2008 |
| First posted | Feb 14, 2006 |
| Last update posted | Mar 3, 2009 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: